SGLT2 Metabolic Longevity Protocol

Protocol Overview

This protocol combines three mechanistically distinct interventions for comprehensive metabolic and longevity optimisation, built on landmark 2024-2025 evidence:

• SGLT2 inhibitor (dapagliflozin) — caloric restriction mimetic, indirect senolytic, telomere preservation
• Akkermansia muciniphila (pasteurised) — gut barrier integrity, insulin sensitivity, GLP-1 enhancement
• Berberine — AMPK activation, lipid optimisation, microbiome modulation

This is an advanced protocol for individuals 45+ with metabolic risk factors who have established baseline care and physician access.

The Three-Mechanism Approach

Why This Combination?

Most metabolic protocols address one pathway at a time. This protocol addresses three:

1. Glucose/insulin axis (SGLT2 inhibitor)
2. Gut-metabolic axis (Akkermansia)
3. AMPK/cellular energy (Berberine)

The mechanisms are largely non-overlapping — providing complementary rather than redundant benefits.

The Evidence Foundation

Zhang et al., Cell Reports Medicine (2025):

• SGLT2 inhibitor henagliflozin in 189 T2D patients
• 90.5% showed telomere lengthening at 26 weeks
• Significant granzyme B elevation (immune surveillance)
• IGFBP-3 increase (reduced IGF-1 signalling)
• First randomised evidence of telomere reversal with any drug

Katsuumi et al., Nature (2024):

• SGLT2 inhibition as indirect senolytic
• Mechanism via PD-L1 downregulation on senescent cells
• Enhanced immune-mediated clearance

Depommier et al., Nature Medicine (2019):

• Pasteurised Akkermansia in 32 obese patients
• 28% improvement in insulin sensitivity over 3 months
• Reduced inflammatory markers
• Improved intestinal barrier function

Component 1: SGLT2 Inhibitor

Drug: Dapagliflozin (Farxiga) or Empagliflozin (Jardiance) Dose: 5-10mg once daily Timing: Morning, with or without food Cycling: Continuous use

Why this dose:

• For non-diabetic longevity use, 5mg may provide most benefits
• Standard 10mg has more clinical trial validation
• Reduces infection risk vs higher doses

What it accomplishes:

• 200-300 kcal/day excreted as glucose
• AMPK and SIRT1 activation (caloric restriction mimicry)
• Indirect senolytic activity via immune surveillance restoration
• IGF-1 signalling reduction
• Cardiovascular and renal protection (established RCT evidence)

Side effects to monitor:

• Genital mycotic infections (5-15% — yeast infections)
• UTIs (modest increase)
• Volume depletion (require adequate hydration)
• Euglycemic DKA (very rare; avoid strict keto diet)

Component 2: Akkermansia muciniphila

Product: Pendulum Akkermansia or equivalent pasteurised form Dose: 10^10 cells/day (10 billion cells) Timing: Morning, fasted or with light meal Cycling: Continuous use; 12-week minimum for measurable effects

Why pasteurised:

• Original 2019 trial showed superior effects vs live form
• Active component Amuc_1100 retains effect after pasteurisation
• More stable formulation
• The form used in positive clinical trial

What it accomplishes:

• Intestinal barrier strengthening
• 28% insulin sensitivity improvement (per Depommier 2019)
• Enhanced GLP-1 secretion (synergistic with metabolic effects)
• Reduced systemic inflammation
• Reduced LPS translocation

Cost consideration:

• $50-80/month for quality products
• One of the more expensive probiotic categories
• Justified by mechanism specificity

Component 3: Berberine

Dose: 500mg three times daily with meals (1500mg total) OR Dihydroberberine 200mg twice daily Timing: With meals Cycling: Continuous use

Form considerations:

• Standard berberine HCl: cheapest, most studied
• Dihydroberberine: 5x better bioavailability
• Berberine phytosome: phospholipid-complexed, enhanced absorption

What it accomplishes:

• AMPK activation (different mechanism than SGLT2)
• Lipid optimisation (LDL reduction)
• Microbiome modulation (different patterns than metformin)
• Mild blood pressure reduction
• Cost-effective metabolic foundation

Component 4 (Foundation): Omega-3 DHA

Dose: 2-3g EPA+DHA daily Timing: With largest fatty meal Form: Triglyceride form, IFOS certified

Why include:

• Synergistic with SGLT2 cardiovascular protection
• Anti-inflammatory amplification
• Supports Akkermansia abundance (positively)
• Foundational longevity supplement

Complete Dosing Schedule

Practical implementation:

• Morning: Dapagliflozin + Akkermansia + Berberine (with breakfast) + Omega-3
• Lunch: Berberine
• Dinner: Berberine + additional Omega-3 if dose split

Pre-Protocol Assessment

Required baseline labs:

• Complete metabolic panel
• Lipid panel (consider ApoB)
• HbA1c
• Fasting insulin (calculate HOMA-IR)
• hs-CRP
• Kidney function (creatinine, eGFR — eGFR must be >30 for SGLT2)
• Liver enzymes (ALT, AST)
• Vitamin B12 (baseline for monitoring)

Required body composition:

• Body weight, waist circumference
• DEXA scan if accessible
• Bioimpedance if DEXA unavailable

Contraindications:

• Type 1 diabetes (DKA risk)
• Severe renal impairment (eGFR <30)
• Recurrent UTIs or genital infections
• Pregnancy/breastfeeding
• Strict ketogenic diet (DKA risk with SGLT2)
• Pancreatitis history (relative)

Monitoring Schedule

Month 1:

• Hydration status check
• Side effect assessment
• Adherence verification

Month 3:

• Complete metabolic panel
• HbA1c
• Lipid panel
• hs-CRP
• Body composition
• Side effect review

Month 6:

• Full baseline panel repeat
• Adjustment based on response
• Continue, modify, or escalate

Annually:

• Comprehensive labs including B12, vitamin D
• Body composition (DEXA)
• Consider biological age markers (GlycanAge, DunedinPACE, Horvath)
• Comprehensive review with physician

Expected Effects Timeline

Weeks 1-4:

• Initial adaptation to SGLT2 (mild diuresis, possible fatigue)
• Akkermansia adaptation (possible mild GI changes)
• Berberine dose tolerance (GI effects if any)
• Modest weight loss begins (1-2 kg from SGLT2 caloric loss)

Months 1-3:

• HbA1c reduction in those with elevated baseline
• Improved fasting glucose
• Lipid improvements (LDL reduction)
• hs-CRP reduction (Akkermansia inflammation effect)
• Continued weight reduction
• Subjective energy improvements

Months 3-6:

• Substantial HbA1c improvements (if elevated)
• Significant cardiovascular biomarker improvements
• Body composition optimisation
• Telomere effects emerging (per Zhang 2025 timeline)

Months 6-12:

• Cumulative metabolic improvements
• Long-term cardiovascular and renal protection
• Body composition stabilisation at new lower baseline
• Possible biological age marker improvements

Practical Considerations

Hydration:

• Critical with SGLT2 use
• 2-3L water daily
• More in hot weather or with exercise

Diet:

• Avoid strict ketogenic diet (DKA risk)
• Mediterranean dietary pattern ideal
• Adequate fibre (supports microbiome including Akkermansia)
• Limit processed foods

Exercise:

• Compatible with all components
• Hydration awareness during exercise
• Resistance training particularly important for body composition

Travel:

• Akkermansia stable at room temperature
• SGLT2 — keep doxa adherence consistent
• Berberine — multiple daily doses require pill organiser

Stacking with Other Protocols

Compatible additions:

• NMN or NR — NAD+ optimisation amplifies SIRT1 activation
• Urolithin A — mitophagy + improved immune function (synergistic with SGLT2 senolytic effects)
• Quercetin/Fisetin (pulsed) — direct senolytic to complement immune-mediated clearance

Caution:

• Rapamycin — careful monitoring, both modulate immune surveillance
• Higher doses of senolytics — coordinate with SGLT2 effects
• GLP-1 agonists (Tirzepatide, Semaglutide) — potentially synergistic but requires physician supervision

Cost Analysis

Annual cost estimate (US pricing 2026):

Significant investment but reflects the comprehensive nature of intervention.

Adjustments by Response

Excellent response (HbA1c normalised, lipids optimised, body composition improved):

• Continue current protocol
• Consider adding senolytic intervention
• Routine monitoring

Partial response:

• Verify adherence
• Consider dose adjustments (within physician guidance)
• Evaluate lifestyle factors
• May add additional supportive compounds

Limited response:

• Detailed metabolic workup
• Consider underlying issues (sleep, stress, hormones)
• Reassess protocol composition

Adverse effects:

• Address specific issues (e.g., infection treatment for SGLT2 yeast infections)
• Dose reduction where appropriate
• Discontinue if intolerable

Who This Protocol Is For

Strong candidates:

• Adults 45+ with metabolic syndrome features
• Pre-diabetes or established type 2 diabetes
• Elevated cardiovascular risk factors
• Family history of premature cardiovascular disease
• Longevity-focused individuals with physician access

Reasonable candidates:

• Adults 40+ seeking comprehensive metabolic optimisation
• Those who have plateaued on simpler interventions
• Individuals with chronic inflammation markers

Not recommended for:

• Lean, metabolically healthy young adults
• Type 1 diabetes
• Severe renal impairment
• Pregnancy/breastfeeding
• Strict ketogenic diet adherents
• Recurrent infection history

Related Research

• SGLT2 Inhibitors: The First Drugs That Reverse Telomere Aging in Humans
• Akkermansia muciniphila: The Next-Generation Probiotic for Metabolic Health
• The Senolytic Stack 2026: Quercetin + Fisetin + SGLT2 Combined Protocol